WO1999055699A1 - Paroxetine 10-camphorsulfonate for treatment of cns disorders - Google Patents

Paroxetine 10-camphorsulfonate for treatment of cns disorders Download PDF

Info

Publication number
WO1999055699A1
WO1999055699A1 PCT/GB1999/001246 GB9901246W WO9955699A1 WO 1999055699 A1 WO1999055699 A1 WO 1999055699A1 GB 9901246 W GB9901246 W GB 9901246W WO 9955699 A1 WO9955699 A1 WO 9955699A1
Authority
WO
WIPO (PCT)
Prior art keywords
paroxetine
camphorsulfonate
solution
salt
treatment
Prior art date
Application number
PCT/GB1999/001246
Other languages
French (fr)
Inventor
Michael Urquhart
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL99343596A priority Critical patent/PL343596A1/en
Priority to IL13901899A priority patent/IL139018A0/en
Priority to EA200001105A priority patent/EA200001105A1/en
Priority to JP2000545859A priority patent/JP2002513020A/en
Priority to KR1020007011750A priority patent/KR20010042929A/en
Priority to EP99918153A priority patent/EP1076659A1/en
Priority to BR9909878-4A priority patent/BR9909878A/en
Priority to SK1590-2000A priority patent/SK15902000A3/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to APAP/P/2000/001958A priority patent/AP2000001958A0/en
Priority to CA002329913A priority patent/CA2329913A1/en
Priority to AU36186/99A priority patent/AU3618699A/en
Publication of WO1999055699A1 publication Critical patent/WO1999055699A1/en
Priority to NO20005351A priority patent/NO20005351D0/en
Priority to BG104973A priority patent/BG104973A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Definitions

  • the present invention relates to a novel compound, to processes for preparing it and to its use in treating medical disorders.
  • 10-camphorsulfonic acid exists in enantiomeric forms and this invention includes salts with both D-(+)-10-camphorsulfonic acid and (lR)-(-)-10-camphorsulfonic acid and racemic mixtures of both salts.
  • novel salt of this invention is provided in non-crystalline form, which may a solid or an oil.
  • the oil is preferably absorbed on a solid carrier, especially a carrier that is usable as a component of a pharmaceutical composition
  • novel salt of this invention is provided in crystalline form.
  • each polymorph forms another aspect of this invention.
  • Paroxetine camphor- 10-sulfonates may be prepared by contacting stoichiometric amounts of the acid and paroxetine free base.
  • the acid or base is in solution, more preferably both are in solution. Elevated temperature can be used to bring the acid into
  • ⁇ 1 - solution but good yields of the salt are obtained by evaporation of some or all of the solvent or by controlled cooling, preferably in stages.
  • Most commonly used solvents are suitable for mobilising paroxetine free base, for example toluene, alcohols such as methanol, ethanol, propan-2-ol, esters such as ethyl acetate, ketones such as acetone and butanone, halogenated hydrocarbons such as dichloromethane, and ethers such as tetrahydrofuran and diethyl ether, but solvents in which camphor- 10-sulfonic acids are very insoluble are preferably avoided.
  • Suitable solvents for camphor- 10-sulfonic acids include water, alcohols, ethyl acetate and acetic acid.
  • the salt may be isolated in solid form by conventional means from a solution thereof obtained as above.
  • the non-crystalline salt may be prepared by precipitation, spray drying, and freeze drying of solutions, or vacuum drying of oils, or solidification of melts obtained from reaction of the free base and the acid.
  • the crystalline salt may be prepared by crystallization or recrystallization from appropriate solvents.
  • Solvates may be returned to the unsolvated salt by heating, for example by oven-drying, or by treatment with a displacement solvent which does not form a solvate.
  • water Prior to the isolation of the paroxetine salt, water may be removed by azeotropic distillation to avoid the formation of hydrates or to obtain the product in anhydrous form.
  • suitable solvents for the solution of the salt are those which form an azeotrope with water such as toluene and propan-2-ol. It should also be appreciated that mixtures of solvents can also be used to aid the azeotropic removal of water.
  • crystallization may be carried out from any solvent which allows formation of the desired crystal structure, using seeds of the desired structure where necessary or desirable.
  • individual polymorphs are preferably crystallized directly from a solution of the salt, although recrystallizing a solution of one polymorph using seeds of another polymorph may also be carried out.
  • -2- Paroxetine free base may be prepared according to the procedures generally outlined in US Patent No 4,007,196 and EP-B-0 223403. D-10-camphorsulfonic acid and L-10- camphorsulfonic acid are commercially available.
  • the compounds of this invention may be used to treat and prevent the following disorders:
  • the present invention further provides a method for treating and/or preventing any one or more of the Disorders by administering an effective and/or prophylactic amount of a salt of the invention to a sufferer in need thereof.
  • the present invention further provides a pharmaceutical composition for use in the treatment and/or prevention of the Disorders which comprises an admixture of a salt of the invention with a pharmaceutically acceptable carrier.
  • the present invention also provides the use of a salt of the invention for treating and/or preventing the Disorders.
  • the present invention also provides the use of a salt of the invention in the manufacture of a medicament for treating and/or preventing the Disorders.
  • the present invention is applied to the treatment of depression, OCD and panic.
  • compositions of this invention are usually adapted for oral administration, but formulations for dissolution for parental administration are also within the scope of this invention.
  • composition is usually presented as a unit dose composition containing from 1 to 200mg of active ingredient calculated on a free base basis, more usually from 5 to lOOmg, for example 10 to 50mg such as 10, 12.5, 15, 20, 25, 30 or 40mg by a human patient. Most preferably unit doses contain 20mg of active ingredient calculated on a free base basis. Such a composition is normally taken from 1 to 6 times daily, for example 2, 3 or 4 times daily so that the total amount of active agent administered is within the range 5 to 400mg of active ingredient calculated on a free base basis. Most preferably the unit dose is taken once a day.
  • Preferred unit dosage forms include tablets or capsules.
  • compositions of this invention may be formulated by conventional methods of admixture such as blending, filling and compressing.
  • Suitable carriers for use in this invention include a diluent, a binder, a disintegrant, a colouring agent, a flavouring agent and/or preservative. These agents may be utilized in conventional manner, for example in a manner similar to that already used for marketed anti-depressant agents.
  • compositions include those described EP-B-0- 223403, and US 4,007,196 in which the products of the present invention may be used as the active ingredients.
  • Example 2 Larger scale preparation of crystalline salt.
  • Example 4 Larger scale preparation of crystalline salt.
  • the tablets are made satisfactorily on a single punch or a Rotary press.
  • Paroxetine 10-camphorsulfonate, Sodium Starch Glycollate and Dicalcium Phosphate Dihydrate are screened and mixed together in a suitable mixer. (Planetary, Cuble or High Energy Shear mixer.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Paroxetine 10-camphorsulfonates are useful in the treatment of certain CNS disorders.

Description

PAROXETINE 10-CAMPHORSULFONATE FOR TREATMENT OF CNS
DISORDERS
The present invention relates to a novel compound, to processes for preparing it and to its use in treating medical disorders.
Pharmaceutical products with antidepressant and anti-Parkinson properties are described in US-A-3912743 and US-A-4007196. An especially important compound among those disclosed is paroxetine, the (-)trans isomer of 4-(4'-fluorophenyl)-3-(3',4'-methylenedioxy- phenoxymethyl)-piperidine. This compound is used in therapy as the hydrochloride salt for the treatment and prophylaxis of inter alia depression, obsessive compulsive disorder (OCD) and panic.
We have now surprisingly discovered a novel salt of paroxetine which may be used as an alternative to the currently marketed hydrochloride, or as an intermediate in the preparation of the hydrochloride.
According to the present invention there is provided a paroxetine camphor 10-sulfonate. 10-camphorsulfonic acid exists in enantiomeric forms and this invention includes salts with both D-(+)-10-camphorsulfonic acid and (lR)-(-)-10-camphorsulfonic acid and racemic mixtures of both salts.
In one aspect the novel salt of this invention is provided in non-crystalline form, which may a solid or an oil. The oil is preferably absorbed on a solid carrier, especially a carrier that is usable as a component of a pharmaceutical composition
In another aspect the novel salt of this invention is provided in crystalline form. When the crystalline form exists as more than one polymorph, each polymorph forms another aspect of this invention.
Paroxetine camphor- 10-sulfonates may be prepared by contacting stoichiometric amounts of the acid and paroxetine free base. Preferably either the acid or base is in solution, more preferably both are in solution. Elevated temperature can be used to bring the acid into
■ 1 - solution, but good yields of the salt are obtained by evaporation of some or all of the solvent or by controlled cooling, preferably in stages. Most commonly used solvents are suitable for mobilising paroxetine free base, for example toluene, alcohols such as methanol, ethanol, propan-2-ol, esters such as ethyl acetate, ketones such as acetone and butanone, halogenated hydrocarbons such as dichloromethane, and ethers such as tetrahydrofuran and diethyl ether, but solvents in which camphor- 10-sulfonic acids are very insoluble are preferably avoided. Suitable solvents for camphor- 10-sulfonic acids include water, alcohols, ethyl acetate and acetic acid.
The salt may be isolated in solid form by conventional means from a solution thereof obtained as above. For example, the non-crystalline salt may be prepared by precipitation, spray drying, and freeze drying of solutions, or vacuum drying of oils, or solidification of melts obtained from reaction of the free base and the acid. The crystalline salt may be prepared by crystallization or recrystallization from appropriate solvents.
When the salt is obtained as a solvate, by association with the solvent in which it is dissolved, such solvate forms a further aspect of this invention. Solvates may be returned to the unsolvated salt by heating, for example by oven-drying, or by treatment with a displacement solvent which does not form a solvate.
Prior to the isolation of the paroxetine salt, water may be removed by azeotropic distillation to avoid the formation of hydrates or to obtain the product in anhydrous form. In that case, suitable solvents for the solution of the salt are those which form an azeotrope with water such as toluene and propan-2-ol. It should also be appreciated that mixtures of solvents can also be used to aid the azeotropic removal of water.
More generally, crystallization may be carried out from any solvent which allows formation of the desired crystal structure, using seeds of the desired structure where necessary or desirable. When polymorphs exist, individual polymorphs are preferably crystallized directly from a solution of the salt, although recrystallizing a solution of one polymorph using seeds of another polymorph may also be carried out.
-2- Paroxetine free base may be prepared according to the procedures generally outlined in US Patent No 4,007,196 and EP-B-0 223403. D-10-camphorsulfonic acid and L-10- camphorsulfonic acid are commercially available.
The compounds of this invention may be used to treat and prevent the following disorders:
Alcoholism Anxiety
Depression Obsessive Compulsive Disorder
Panic Disorder Chronic Pain
Obesity Senile Dementia
Migraine Bulimia
Anorexia Social Phobia
Pre-Menstrual Syndrome (PMS) Adolescent Depression
Trichotillomania Dysthymia
Substance Abuse
These disorders are herein after referred to as "the Disorders"
The present invention further provides a method for treating and/or preventing any one or more of the Disorders by administering an effective and/or prophylactic amount of a salt of the invention to a sufferer in need thereof.
The present invention further provides a pharmaceutical composition for use in the treatment and/or prevention of the Disorders which comprises an admixture of a salt of the invention with a pharmaceutically acceptable carrier.
The present invention also provides the use of a salt of the invention for treating and/or preventing the Disorders.
The present invention also provides the use of a salt of the invention in the manufacture of a medicament for treating and/or preventing the Disorders.
Most suitably the present invention is applied to the treatment of depression, OCD and panic.
The compositions of this invention are usually adapted for oral administration, but formulations for dissolution for parental administration are also within the scope of this invention.
-4- The composition is usually presented as a unit dose composition containing from 1 to 200mg of active ingredient calculated on a free base basis, more usually from 5 to lOOmg, for example 10 to 50mg such as 10, 12.5, 15, 20, 25, 30 or 40mg by a human patient. Most preferably unit doses contain 20mg of active ingredient calculated on a free base basis. Such a composition is normally taken from 1 to 6 times daily, for example 2, 3 or 4 times daily so that the total amount of active agent administered is within the range 5 to 400mg of active ingredient calculated on a free base basis. Most preferably the unit dose is taken once a day.
Preferred unit dosage forms include tablets or capsules.
The compositions of this invention may be formulated by conventional methods of admixture such as blending, filling and compressing.
Suitable carriers for use in this invention include a diluent, a binder, a disintegrant, a colouring agent, a flavouring agent and/or preservative. These agents may be utilized in conventional manner, for example in a manner similar to that already used for marketed anti-depressant agents.
Specific examples of pharmaceutical compositions include those described EP-B-0- 223403, and US 4,007,196 in which the products of the present invention may be used as the active ingredients.
The following Examples illustrate the present invention:
Example 1: Preparation of crystalline paroxetine D-(+)-10-camphorsulfonate
A solution of paroxetine base in toluene (5 ml, 6.38 mmol) was added to a solution of D(+)-10-camphorsulfonic acid (1.48 g, 6.38 mmol) in methanol (20 ml). The mixture was allowed to stand at room temperature for 20 min. and the solvent was removed in vacuo. The residue was diluted with toluene (20 ml) and the solvent removed in vacuo.
-5- Trituration with diethyl ether (c. 50 ml) and filtration under nitrogen gave a white solid which was washed with diethyl ether (2 x 20 ml) and dried in a vacuum desiccator.
Yield 3.50g.
Example 2: Larger scale preparation of crystalline salt.
A solution of paroxetine base in toluene (75 ml, 95.7 mmol) was added to a solution of D(+)-10-camphorsulfonic acid (22.2 g, 95.7 mmol) in methanol (300 ml). The solvent was removed in vacuo, the residue diluted with toluene (100 ml), and the solvent removed in vacuo. Trituration with diethyl ether (c. 350 ml) gave a white solid which was filtered, washed with diethyl ether (2 x 100 ml) and vacuum dried.
Yield 54.46g
H NMR (CDCI3) showed a ratio between D(+)-10-camphorsulfonic acid and paroxetine of l:l.
m. p. 109°C (phase change).
IR nujol mull:
Bands at 1740, 1501, 1464, 1376, 1183, 1034, 828, 768, 601, 515 cm"1.
X-ray diffractogram major peaks (CuK.2α):
Angle [°2Θ] ReUnt [%]
5.965 39.9
6.400 56.5
6.665 36.8
11.880 44.0
Figure imgf000008_0001
-6- 13.765 31.5
15.055 29.1
16.200 38.4
16.945 68.0
17.970 39.2
19.360 28.5
20.825 32.8
21.630 43.0
22.270 36.8
23.365 21.2
24.255 100.0
25.190 75.4
27.105 35.1
29.720 15.5
30.360 18.6
32.360 15.7
32.800 14.9
Figure imgf000009_0001
Example 3: Preparation of crystalline paroxetine (lR)-(-)-10-camphorsulfonate
A solution of paroxetine base in toluene (5 ml, 6.38 mmol) was added to a solution of (1R)- (-)-lO-camphorsulfonic acid (1.48 g, 6.38 mmol) in methanol (20 ml). The mixture was allowed to stand at room temperature for 20 minutes and the solvent was then removed in vacuo. The residual solid was diluted with toluene (20 ml) and the solvent removed in vacuo. Trituration with diethyl ether (c. 50 ml) and filtration under nitrogen gave a white solid which was washed with diethyl ether (2 x 20 ml) and dried at reduced pressure.
Yield 3.18g.
Example 4: Larger scale preparation of crystalline salt.
-7- A solution of paroxetine base in toluene (66 ml, 84.16 mmol) was added to a solution of (lR)-(-)-10-camphorsulfonic acid (19.5g, 83.94 mmol) in methanol (200 ml). The mixture was allowed to stand at ambient temperature for 40 min. and then the solvent was removed by evaporation. The residual solid was triturated with diethyl ether (c. 350 ml), stirred at ambient temperature for 16 hours and filtered to give a white solid which was washed with diethyl ether (2 x 100 ml) and dried at reduced pressure.
Yield 43.77g
! H NMR (CDC13) showed a ratio between ( 1 R)-(-)- 10-camphorsulfonic acid and paroxetine of 1 : 1.
m. p. 136 - 139°C.
IR nujol mull:
Bands at 1736, 1604, 1503, 1462, 1376, 1278, 1194, 1037, 827, 670, 602, 538 cm"1.
-8- X-ray diffractogram major peaks (CuK.2 ):
Angle [°2Θ] ReLInt [%]
6.105 19.0
6.645 14.2
13.615 10.0
15.715 17.0
16.785 100.0
17.175 53.2
17.735 16.7
19.205 10.5
19.550 18.9
20.050 13.6
20.430 13.0
21.200 25.5
21.760 14.3
22.270 16.4
23.350 13.2
24.345 42.7
24.905 19.8
25.160 26.1
25.925 19.4
29.015 10.8
30.860 10.6
Figure imgf000011_0001
Example 5: preparation of tablets
INGREDIENTS 20 mg Tablet 30mg Tablet
Figure imgf000011_0002
-9- Paroxetine 10-camphorsulfonate 20.00 mg 30.0 mg
(based on free base) (based on free base)
Dicalcium Phosphate (DCP) 83.34 mg 125.0 mg
Microcrystalline Cellulose 50.67 mg 76.0 mg
Sodium Starch Glycollate 8.34 mg 12.5 mg
Magnesium Stearate 1.67 mg 2.5 mg
Figure imgf000012_0001
Commercial source of the ingredients
Dicalcium Phosphate Dihydrate Emcompress or Ditab* Microcrystalline Cellulose Avicel PH 102* Sodium Starch Glycollate Explotab.*
* Tradenames
Method
1. Pass DCP through a screen and weigh it into a Planetary mixer.
2. Add 30 mesh Paroxetine 10-camphorsulfonate to the bowl.
3. Add 20 mesh Avicel and Explotab and mix all the powders for 10 minutes. 4. Add magnesium stearate and mix for 5 minutes.
Tablet into Pentagonal Tablets using the following punches:
30 mg Tablet 9.5 mm Circumcircle 20 mg Tablet 8.25 mm Circumcircle
The tablets are made satisfactorily on a single punch or a Rotary press.
■10- Example 6: preparation of tablets
INGREDIENTS 10 mg Tablet 20 mg Tablet 30mg Tablet
Paroxetine 10- 10 mg 20 mg 30 mg camphorsulfonate (as on free base) (as on free base) (as on free base)
Sodium Starch Glycollate 2.98 mg 5.95 mg 8.93 mg
Granular Dicalcium
Phosphate 158.88 mg 317.75 mg 476.63 mg
(DITAB) or Dicafos
Magnesium Stearate 1.75 mg 3.50 mg 5.25 mg
Figure imgf000013_0001
Method
Paroxetine 10-camphorsulfonate, Sodium Starch Glycollate and Dicalcium Phosphate Dihydrate are screened and mixed together in a suitable mixer. (Planetary, Cuble or High Energy Shear mixer.)
Add Magnesium Stearate and compress it into a tablet using a single punch or Rotary Tablet machine.
-1 1-

Claims

1. A paroxetine 10-camphorsulfonate.
2. Paroxetine (D)-(+)- 10-camphorsulfonate.
3. Paroxetine ( 1 R)-(-)- 10-camphorsulfonate .
4. A compound according to claim 1 , 2 or 3 in non-crystalline form.
5. A compound according to claim 1, 2 or 3 in crystalline form.
6. A process for the preparation of a compound as claimed in claim 1 , 2, 3 or 4 by precipitation, spray drying or freeze drying a solution of a paroxetine 10-camphorsulfonate, or by vacuum drying of oils of paroxetine 10-camphorsulfonate, or solidification of melts of a paroxetine 10-camphorsulfonate.
7. A process for the preparation of a compound as claimed in claim 1, 2, 3 or 5 by crystallization or re-crystallization from a solution of a paroxetine 10-camphorsulfonate.
8. A process according to claim 6 or 7 in which the solution, oil or melt of a paroxetine 10-camphorsulfonate is prepared by treating paroxetine free base with 10- camphorsulfonic acid.
9. A method for treating and/or preventing any one or more of the Disorders by administering an effective and/or prophylactic amount of a paroxetine 10- camphorsulfonate to a sufferer in need thereof.
-12-
PCT/GB1999/001246 1998-04-25 1999-04-23 Paroxetine 10-camphorsulfonate for treatment of cns disorders WO1999055699A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
BR9909878-4A BR9909878A (en) 1998-04-25 1999-04-23 10-paroxetine camphosulfonate for treatment of central nervous system disorders
EA200001105A EA200001105A1 (en) 1998-04-25 1999-04-23 10-Camforsulfonat Paroxetine for the treatment of CNS disorders
JP2000545859A JP2002513020A (en) 1998-04-25 1999-04-23 Paroxetine 10-camphorsulfonate for the treatment of CNS diseases
KR1020007011750A KR20010042929A (en) 1998-04-25 1999-04-23 Paroxetine 10-Camphorsulfonate For Treatment Of CNS Disorders
EP99918153A EP1076659A1 (en) 1998-04-25 1999-04-23 Paroxetine 10-camphorsulfonate for treatment of cns disorders
PL99343596A PL343596A1 (en) 1998-04-25 1999-04-23 Paroxetine 10-camphorsulfonate for treatment of cns disorders
SK1590-2000A SK15902000A3 (en) 1998-04-25 1999-04-23 Paroxetine 10-camphorsulfonate for treatment of cns disorders
IL13901899A IL139018A0 (en) 1998-04-25 1999-04-23 Paroxetine 10-camphorsulfonate for treatment of cns disorders
APAP/P/2000/001958A AP2000001958A0 (en) 1998-04-25 1999-04-23 Paroxetine 10-camphorsulfornate for treatment of CNS disorders.
CA002329913A CA2329913A1 (en) 1998-04-25 1999-04-23 Paroxetine 10-camphorsulfonate for treatment of cns disorders
AU36186/99A AU3618699A (en) 1998-04-25 1999-04-23 Paroxetine 10-camphorsulfonate for treatment of cns disorders
NO20005351A NO20005351D0 (en) 1998-04-25 2000-10-24 Paroxetine 10-camphor sulfonate for the treatment of CNS disorders
BG104973A BG104973A (en) 1998-04-25 2000-11-21 Paroxetine 10-camphorsulfonate for treatmnent of cns disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9808894.1 1998-04-25
GBGB9808894.1A GB9808894D0 (en) 1998-04-25 1998-04-25 Novel compound

Publications (1)

Publication Number Publication Date
WO1999055699A1 true WO1999055699A1 (en) 1999-11-04

Family

ID=10831007

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/001246 WO1999055699A1 (en) 1998-04-25 1999-04-23 Paroxetine 10-camphorsulfonate for treatment of cns disorders

Country Status (18)

Country Link
EP (1) EP1076659A1 (en)
JP (1) JP2002513020A (en)
KR (1) KR20010042929A (en)
CN (1) CN1306530A (en)
AP (1) AP2000001958A0 (en)
AU (1) AU3618699A (en)
BG (1) BG104973A (en)
BR (1) BR9909878A (en)
CA (1) CA2329913A1 (en)
EA (1) EA200001105A1 (en)
GB (1) GB9808894D0 (en)
HU (1) HUP0102298A2 (en)
IL (1) IL139018A0 (en)
NO (1) NO20005351D0 (en)
PL (1) PL343596A1 (en)
SK (1) SK15902000A3 (en)
TR (1) TR200003083T2 (en)
WO (1) WO1999055699A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229980B2 (en) 2004-09-21 2007-06-12 Chong Kun Dang Pharmaceutical Corp. Paroxetine cholate or cholic acid derivative salts, and composition comprising paroxetine and cholic acid or derivative thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104402708A (en) * 2014-12-07 2015-03-11 河南领先科技药业有限公司 Production method for sodium camphorate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0188081A2 (en) * 1984-12-04 1986-07-23 Novo Nordisk A/S Use of paroxetine for the manufacture of a medicament for the treatment of obesity
EP0223403A2 (en) * 1985-10-25 1987-05-27 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
WO1998001424A1 (en) * 1996-07-08 1998-01-15 Richter Gedeon Vegyészeti Gyár Rt. N-benzylpiperidine and tetrahydropyridine derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0188081A2 (en) * 1984-12-04 1986-07-23 Novo Nordisk A/S Use of paroxetine for the manufacture of a medicament for the treatment of obesity
EP0223403A2 (en) * 1985-10-25 1987-05-27 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
WO1998001424A1 (en) * 1996-07-08 1998-01-15 Richter Gedeon Vegyészeti Gyár Rt. N-benzylpiperidine and tetrahydropyridine derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229980B2 (en) 2004-09-21 2007-06-12 Chong Kun Dang Pharmaceutical Corp. Paroxetine cholate or cholic acid derivative salts, and composition comprising paroxetine and cholic acid or derivative thereof

Also Published As

Publication number Publication date
PL343596A1 (en) 2001-08-27
SK15902000A3 (en) 2001-05-10
NO20005351L (en) 2000-10-24
TR200003083T2 (en) 2001-02-21
CA2329913A1 (en) 1999-11-04
AU3618699A (en) 1999-11-16
AP2000001958A0 (en) 2000-12-31
EP1076659A1 (en) 2001-02-21
BR9909878A (en) 2000-12-26
IL139018A0 (en) 2001-11-25
BG104973A (en) 2001-09-28
HUP0102298A2 (en) 2002-05-29
KR20010042929A (en) 2001-05-25
GB9808894D0 (en) 1998-06-24
EA200001105A1 (en) 2001-04-23
JP2002513020A (en) 2002-05-08
NO20005351D0 (en) 2000-10-24
CN1306530A (en) 2001-08-01

Similar Documents

Publication Publication Date Title
EP1414454A1 (en) Paroxetine glycyrrhizinate
EP1053234A1 (en) Salts of paroxetine
EP1137636A1 (en) Process for preparation of paroxetine maleate
CA2327450A1 (en) Paroxetine maleate
EP1089995A1 (en) Paroxetine ascorbate
EP1076659A1 (en) Paroxetine 10-camphorsulfonate for treatment of cns disorders
MXPA00010435A (en) Paroxetine 10-camphorsulfonate for treatment of cns disorders
MXPA00010439A (en) Paroxetine ascorbate
US20030028027A1 (en) Paroxetine maleate
EP1135383B1 (en) Mixed paroxetine propan-2-ol solvates
AU2528899A (en) Salts of paroxetine
MXPA00009884A (en) Paroxetine maleate
MXPA00007719A (en) Salts of paroxetine
CZ20003942A3 (en) Paroxetine ascorbate
WO2001014369A2 (en) Process for the preparation of paroxetin.hcl
CZ20003941A3 (en) Paroxetine 10-camphorsulfonate for treating disorders of central neural system
WO2001025201A1 (en) Process for the preparation of paroxetin intermediate
WO2001025230A1 (en) Process for the preparation of paroxetine hydrochloride acetone solvate
CZ20003722A3 (en) Paroxetine maleate
WO2000032596A1 (en) Amine salts of paroxetine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99807798.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 507457

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 139018

Country of ref document: IL

Ref document number: 1999918153

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09673383

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 36186/99

Country of ref document: AU

Ref document number: 200005780

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 15902000

Country of ref document: SK

Ref document number: 2000/03083

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2329913

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020007011750

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/010435

Country of ref document: MX

Ref document number: PV2000-3941

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 200001105

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1999918153

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-3941

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007011750

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999918153

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2000-3941

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020007011750

Country of ref document: KR